ARTICLE | Finance
No stone left unturned
Why Versant is backing Turnstone's oncolytic virus
November 2, 2015 8:00 AM UTC
Versant Ventures added to its Canada playbook last week by backing a biotech that has been working in stealth mode to develop an oncolytic virus that is expected to be more potent than first-generation products.
The VC led Turnstone Biologics Inc.'s C$11.3 million ($8.6 million) series A round and set aside an additional C$13.7 million ($10.4 million) in reserve for the company. Seed investor FACIT also participated...